1. Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
- Author
-
Tiarne van de Walle, Mohanraj Ramachandran, Anna Dimberg, Magnus Essand, Ilkka Pietilä, and Alessandra Vaccaro
- Subjects
Mini Review ,T-Lymphocytes ,brain ,medicine.medical_treatment ,Immunology ,Central nervous system ,Brain tumor ,Priming (immunology) ,Cancer immunotherapy ,glioma ,Glioma ,Tumor Microenvironment ,medicine ,Animals ,Humans ,Immunology and Allergy ,tertiary lymphoid structure ,Cancer och onkologi ,Tumor microenvironment ,Brain Neoplasms ,business.industry ,glioblastoma ,Immunology in the medical area ,Immunotherapy ,RC581-607 ,central nervous system ,medicine.disease ,Tertiary Lymphoid Structures ,Lymphatic system ,medicine.anatomical_structure ,Immunologi inom det medicinska området ,Cancer and Oncology ,Cancer research ,immunotherapy ,Immunologic diseases. Allergy ,business - Abstract
Glioblastoma is the most common and aggressive brain tumor, which is uniformly lethal due to its extreme invasiveness and the absence of curative therapies. Immune checkpoint inhibitors have not yet proven efficacious for glioblastoma patients, due in part to the low prevalence of tumor-reactive T cells within the tumor microenvironment. The priming of tumor antigen-directed T cells in the cervical lymph nodes is complicated by the shortage of dendritic cells and lack of appropriate lymphatic vessels within the brain parenchyma. However, recent data suggest that naive T cells may also be primed within brain tumor-associated tertiary lymphoid structures. Here, we review the current understanding of the formation of these structures within the central nervous system, and hypothesize that promotion of tertiary lymphoid structures could enhance priming of tumor antigen-targeted T cells and sensitize glioblastomas to cancer immunotherapy.
- Published
- 2021
- Full Text
- View/download PDF